Atara Biotherapeutics Inc. (NASDAQ:ATRA) CFO John Mcgrath sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 12th. The shares were sold at an average price of $17.47, for a total transaction of $87,350.00. Following the transaction, the chief financial officer now directly owns 96,823 shares in the company, valued at $1,691,497.81. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Shares of Atara Biotherapeutics Inc. (NASDAQ:ATRA) opened at 15.75 on Wednesday. The firm’s market capitalization is $453.77 million. The stock has a 50 day moving average of $19.42 and a 200-day moving average of $20.21. Atara Biotherapeutics Inc. has a 52 week low of $13.31 and a 52 week high of $40.80.
Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Monday, August 8th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by $0.05. Equities analysts anticipate that Atara Biotherapeutics Inc. will post ($2.85) earnings per share for the current fiscal year.
A number of analysts have issued reports on the stock. JMP Securities reiterated a “buy” rating on shares of Atara Biotherapeutics in a research note on Saturday, July 9th. Zacks Investment Research upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, September 2nd. Jefferies Group reiterated a “buy” rating and issued a $25.00 target price on shares of Atara Biotherapeutics in a research note on Tuesday, August 9th. Goldman Sachs Group Inc. cut shares of Atara Biotherapeutics from a “neutral” rating to a “sell” rating and reduced their target price for the company from $23.00 to $16.00 in a research note on Thursday, September 15th. Finally, Citigroup Inc. lifted their target price on shares of Atara Biotherapeutics from $8.00 to $10.00 and gave the company a “sell” rating in a research note on Friday, August 19th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $26.14.
A number of hedge funds have recently modified their holdings of the company. Barclays PLC boosted its stake in shares of Atara Biotherapeutics by 2,266.0% in the second quarter. Barclays PLC now owns 4,803 shares of the company’s stock worth $108,000 after buying an additional 4,600 shares during the period. BlackRock Inc. boosted its stake in shares of Atara Biotherapeutics by 464.3% in the second quarter. BlackRock Inc. now owns 6,100 shares of the company’s stock worth $137,000 after buying an additional 5,019 shares during the period. PNC Financial Services Group Inc. boosted its stake in shares of Atara Biotherapeutics by 6,736.5% in the second quarter. PNC Financial Services Group Inc. now owns 6,563 shares of the company’s stock worth $148,000 after buying an additional 6,467 shares during the period. Creative Planning bought a new stake in shares of Atara Biotherapeutics during the third quarter worth about $213,000. Finally, Franklin Street Advisors Inc. NC bought a new stake in shares of Atara Biotherapeutics during the third quarter worth about $214,000. 75.58% of the stock is currently owned by institutional investors and hedge funds.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.